Expression of Vascular Endothelial Growth Factor (VEGF) and Epidermal Growth Factor Receptor (EGFR) is an Independent Prognostic Indicator of Worse Outcome in Gastric Cancer Patients (original) (raw)
Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics. CA Cancer J Clin 2006; 56:106–130 ArticlePubMed Google Scholar
Roukos DH, Kappas AM. Perspectives in the treatment of gastric cancer. Nat Clin Pract Oncol 2005; 2:98–107 ArticlePubMed Google Scholar
Hartgrink HH, van de Velde CJ. Status of extended lymph node dissection: locoregional control is the only way to survive gastric cancer. J Surg Oncol 2005; 90:153–165 ArticlePubMed Google Scholar
Novotny AR, Schuhmacher C, Bush R, Kattan MW, Brennan MF, Siewert JR. Predicting individual survival after gastric cancer resection: validation of a US-derived nomogram at a single high-volume center in Europe. Ann Surg 2006; 243:74–81 ArticlePubMed Google Scholar
Ajani JA, Mansfield PF, Crane CH, et al. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol 2005; 23:1237–1244 ArticlePubMedCAS Google Scholar
Allal AS, Zwahlen D, Brundler MA, de Peyer R, Morel P, Huber O, Roth AD. Neoadjuvant radiochemotherapy for locally advanced gastric cancer: long-term results of a phase I trial. Int J Radiat Oncol Biol Phys 2005; 63:1286–1289 ArticlePubMed Google Scholar
Kim S, Lim DH, Lee J, et al. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys 2005; 63:1279–1285 ArticlePubMed Google Scholar
Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355:11–20 ArticlePubMedCAS Google Scholar
Hartgrink HH, van de Velde CJ, Putter H, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized duthc gastric cancer group trial. J Clin Oncol 2004; 22:2069–2077 ArticlePubMedCAS Google Scholar
Hundahl SA, Wanebo HJ. Changing gastric cancer treatment in the United States and the pursuit of quality. Eur J Surg Oncol 2005; 31:605–615 ArticlePubMedCAS Google Scholar
Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and a meta-analysis based on aggregate data. J Clin Oncol 2006; 24:2903–2909 ArticlePubMedCAS Google Scholar
Chong G, Cunningham D. Gastrointestinal cancer: recent developments in medical oncology. Eur J Surg Oncol 2005; 31:453–460 ArticlePubMedCAS Google Scholar
Sutter AP, Zeitz M, Scherübl H. Recent results in understanding molecular patways in the medical treatment of esophageal and gastric cancer. Onkologie 2004; 27:17–21 ArticlePubMedCAS Google Scholar
Jüttner S, Wißmann C, Jöns T, et al. Vascular endothelial growth factor-D and ist receptor VEGF-3: two novel independent prognostic markers in gastric adenocarcinoma. J Clin Oncol 2006; 24:228–239 ArticlePubMedCAS Google Scholar
Wang TB, Deng MH, Qiu WS, Dong WG. Association of serum vascular endothelial growth factor-C and lymphatic vessel density with lymph node metastasis and prognosis of patients with gastric cancer. World J Gastroenterol 2007; 13:1794–1798 PubMedCAS Google Scholar
Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005; 23:2445–2459 ArticlePubMedCAS Google Scholar
Tzanakis N, Gazouli M, Rallis G, et al. Vascular endothelial growth factor polymorphisms in gastric cancer development, prognosis, and survival. J Surg Oncol 2006; 94:624–630 ArticlePubMedCAS Google Scholar
Ding S, Li C, Lin S, et al. Distinct roles of VEGF-A and VEGF-C in tumour metastasis of gastric carcinoma. Oncol Rep 2007; 17:369–375 PubMedCAS Google Scholar
Saito H, Osaki T, Murakami D, et al. Prediction of sites of recurrence in gastric carcinoma using immunohistochemical parameters. J Surg Oncol 2007; 95:123–128 ArticlePubMedCAS Google Scholar
Kondo K, Kaneko T, Baba M, Konno H. VEGF-C and VEGF-A synergistically enhance lymph node metastasis of gastric cancer. Biol Pharm Bull 2007; 30:633–637 ArticlePubMedCAS Google Scholar
Galizia G, Lieto E, Orditura M, et al. Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery. World J Surg 2007; 31:1458–1468 ArticlePubMed Google Scholar
Boku N, Ohtsu A, Yoshida S, et al. Significance of biological markers for predicting prognosis and selecting chemotherapy regimens of advanced gastric cancer patients between continuous infusion of 5-FU and a combination of 5-FU and cisplatin. Jpn J Clin Oncol 2007; 37:275–281 ArticlePubMed Google Scholar
Fondevila C, Metges JP, Fuster JJ, et al. p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer. Br J Cancer 2004; 90:206–215 ArticlePubMedCAS Google Scholar
Lang SA, Klein D, Moser C, et al. Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo. Mol Cancer Ther 2007; 6:1123–1132 ArticlePubMedCAS Google Scholar
Ito R, Nakayama H, Yoshida K, Matsumura S, Oda N, Yasui W. Expression of Cbl linking with the epidermal growth factor receptor system is associated with tumor progression and poor prognosis of human gastric carcinoma. Virchows Arch 2004; 444:324–331 ArticlePubMedCAS Google Scholar
Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21:2787–2799 ArticlePubMedCAS Google Scholar
Romano M, Ricci V, Zarrilli R. Mechanisms of disease: Helicobacter pylori-related gastric carcinogenesis–implications for chemoprevention. Nat Clin Pract Gastroenterol Hepatol 2006; 3:622–632 ArticlePubMedCAS Google Scholar
Grogg KL, Lohse CM, Pankratz VS, Halling KC, Smyrk TC. Lymphocyte-rich gastric cancer: associations with Epstein-Barr virus, microsatellite instability, histology, and survival. Mod Pathol 2003; 16:641–651 ArticlePubMed Google Scholar
Hiyama T, Tanaka S, Yoshihara M, et al. Chromosomal and microsatellite instability in sporadic gastric cancer. J Gastroenterol Hepatol 2004; 19:756–760 ArticlePubMedCAS Google Scholar
AJCC Cancer staging manual. 6th Edition. Ed. Springer-Verlag., pp.99–106, 2002
Galizia G, Lieto E, Ferrarraccio F, et al. Determination of molecular marker expression can predict clinical outcome in colon carcinomas. Clin Cancer Res 2004; 10:3490–3499 ArticlePubMedCAS Google Scholar
Galizia G, Lieto E, Ferrarraccio F, et al. Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery. Ann Surg Oncol 2006; 13:823–835 ArticlePubMed Google Scholar
Chan YH. Biostatistics 203. Survival analysis. Singapore Med J 2004; 45:249–256 PubMedCAS Google Scholar
Briasoulis E, Liakakos T, Dova L, Fatouros M, Tsekeris P, Roukos DH, Kappas AM. Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Rev Anticancer Ther 2006; 6:931–939 ArticlePubMed Google Scholar
McCarty MF, Wey J, Stoeltzing O, et al. ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer. Mol Cancer Ther 2004; 3:1041–1048 PubMedCAS Google Scholar
Ciardiello F, Troiani T, Bianco R, et al. Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy. Ann Oncol 2006; 17(suppl_7):vii109–vii114 ArticlePubMed Google Scholar